| pubmed-article:19192342 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19192342 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:19192342 | lifeskim:mentions | umls-concept:C0029045 | lld:lifeskim |
| pubmed-article:19192342 | lifeskim:mentions | umls-concept:C1328813 | lld:lifeskim |
| pubmed-article:19192342 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19192342 | pubmed:dateCreated | 2009-2-4 | lld:pubmed |
| pubmed-article:19192342 | pubmed:abstractText | The aim of the current study was to evaluate whether near-infrared (NIR) spectroscopy-generated metabolomic data obtained from oocyte culture samples would correlate with nuclear maturity status and derived embryo development. A total of 412 oocyte culture samples were collected from 43 patient cycles. Metabolomic profiles of metaphase I and II oocytes were obtained by NIR spectroscopy and were significantly different from each other and from profiles of prophase I (germinal vesicle) oocytes (P +/- 0.001 at the 95% confidence interval). Additionally, NIR spectroscopic analysis of culture medium of oocytes that developed to grade A embryos on day 3 demonstrated significantly higher viability indices (0.62 +/- 0.23) than those that developed to grades C/D (0.42 +/- 0.26; P < 0.006); and on day 5 grade A (0.37 +/- 0.20) was also higher than grades C/D (0.14 +/- 0.21; P < 0.02). Metabolomic profiles of oocytes that resulted in pregnancy had higher viability indices (0.87 +/- 0.27) than those that did not (0.44 +/- 0.17; P < 0.0001). The results of the current study demonstrate that metabolomic profiling from spent culture medium of the oocyte is related to nuclear maturity, is able to predict embryo development at day 3 and day 5 stages, and relates to embryo viability. | lld:pubmed |
| pubmed-article:19192342 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19192342 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19192342 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19192342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19192342 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19192342 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19192342 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:19192342 | pubmed:issn | 1472-6491 | lld:pubmed |
| pubmed-article:19192342 | pubmed:author | pubmed-author:GrecoErmannoE | lld:pubmed |
| pubmed-article:19192342 | pubmed:author | pubmed-author:BehrBarryB | lld:pubmed |
| pubmed-article:19192342 | pubmed:author | pubmed-author:NagyZsolt... | lld:pubmed |
| pubmed-article:19192342 | pubmed:author | pubmed-author:RoosPieterP | lld:pubmed |
| pubmed-article:19192342 | pubmed:author | pubmed-author:DasigJennifer... | lld:pubmed |
| pubmed-article:19192342 | pubmed:author | pubmed-author:Jones-ColonSt... | lld:pubmed |
| pubmed-article:19192342 | pubmed:author | pubmed-author:BotrosLucyL | lld:pubmed |
| pubmed-article:19192342 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19192342 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:19192342 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19192342 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19192342 | pubmed:pagination | 219-25 | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:meshHeading | pubmed-meshheading:19192342... | lld:pubmed |
| pubmed-article:19192342 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19192342 | pubmed:articleTitle | Metabolomic assessment of oocyte viability. | lld:pubmed |
| pubmed-article:19192342 | pubmed:affiliation | Reproductive Biology Associates, Assisted Reproduction, 1150 Lake Hearn Drive, Suite 600, Atlanta, GA 30342, USA. peter.nagy@rba-online.com | lld:pubmed |
| pubmed-article:19192342 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19192342 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19192342 | lld:pubmed |
